Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Valeant Pharmaceuticals North America |
---|---|
Information provided by: | Valeant Pharmaceuticals North America |
ClinicalTrials.gov Identifier: | NCT00310388 |
The purpose of this study is to evaluate the safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures, who completed the VRX-RET-E22-302 double-blind study. The efficacy of long-term treatment with retigabine and patient quality of life will also be assessed.
Condition | Intervention | Phase |
---|---|---|
Epilepsies, Partial |
Drug: Retigabine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-Onset Seizures (Extension of Study VRX-RET-E22-302) |
Estimated Enrollment: | 510 |
Study Start Date: | July 2006 |
Estimated Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Retigabine: Experimental |
Drug: Retigabine
Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patients receives between 600 and 1200 mg of retigabine per day. The duration will be until the completion of the trial, or until the patient withdraws from the trial.
|
This Phase 3 trial is an open-label extension study of the placebo-controlled, double-blind VRX-RET-E22-302 trial. Patients who have completed the VRX-RET-E22-302 trial and who meet inclusion and exclusion criteria will be treated with 600-1200 mg/day of retigabine as an adjunct therapy to their current antiepileptic drugs (AEDs) or vagal nerve stimulation. Treatment will be continued until retigabine is commercially available, or until the program is discontinued. Patients will be recruited from 55-60 sites in Europe, Israel, Australia, and South Africa. The safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures will be evaluated. In addition, the efficacy of long-term treatment with retigabine and patient quality of life will be assessed.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Valeant Pharmaceuticals ( Hank Mansbach, MD ) |
Study ID Numbers: | VRX-RET-E22-304, EUDRACT No. 2006-000956-42 |
Study First Received: | March 30, 2006 |
Last Updated: | February 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00310388 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Partial Seizures Complex Partial Seizures Epilepsy Anticonvulsant Potassium Channels |
Epilepsies, Partial Epilepsy Seizures Central Nervous System Diseases |
D 23129 Brain Diseases Anticonvulsants |
Epilepsies, Partial Epilepsy Therapeutic Uses Nervous System Diseases Central Nervous System Diseases |
D 23129 Brain Diseases Central Nervous System Agents Pharmacologic Actions Anticonvulsants |